Could TREM-1 be a novel marker in the diagnosis of fibromyalgia?: A cross-sectional study

• Published in: Medicine (Baltimore) 2024-07, Vol.103 (28), p.e38806
• Main Authors: Aydogan Baykara, Rabia, Kiran, Tuğba Raika, Otlu, Önder, Erdem, Mehmet, Pihtili Taş, Nevsun
• Format: Article
• Language: English
• Subjects: Adult; Biomarkers - blood; Cross-Sectional Studies; Female; Fibromyalgia - blood; Fibromyalgia - diagnosis; Humans; Male; Middle Aged; ROC Curve; Severity of Illness Index; Triggering Receptor Expressed on Myeloid Cells-1 - blood
• ISSN: 0025-7974; 1536-5964; 1536-5964
• DOI: 10.1097/MD.0000000000038806

Triggering receptors expressed on myeloid cells-1 (TREM-1) are transmembrane molecules expressed in cells of the immune system. Activation of TREM-1 leads to the release of pro-inflammatory mediators, which act as amplifiers of inflammation and thereby contribute to the pathogenesis of various diseases, whether inflammatory or not. This study explored the role of TREM-1 in the etiopathogenic context of fibromyalgia syndrome (FMS) and its association with disease activity. This randomized controlled and observational study included 45 patients diagnosed with FMS according to the 2016 American College of Rheumatology criteria. Serum TREM-1 levels were assessed using ELISA, and disease activity was measured using various scales such as the fibromyalgia impact questionnaire (FIQ). Patients were divided into 2 groups according to disease severity based on the FIQ score. Compared to a control group of 46 healthy individuals, patients with FMS exhibited significantly elevated concentrations of TREM-1 (mean ± SD = 216.97 pg/mL ± 16.04), P